The team believe that their findings point to a ‘transferability ‘of the malignancy risk gene signature between breast cancer and NSCLC, ‘not unique characteristic derived in other gene signatures for different types of tumors seen. ‘ – Chen said: ‘To the best of our knowledge, our study is the first to provide a high level of consistency of the gene signature on both breast cancer and NSCLC show is the gene signature showed a statistically significant association with overall survival and. Other clinical predictors in NSCLC. ‘.
Better prognostic tools were required to both patients with a high likelihood of relapse and those who would benefit from adjuvant chemotherapy. .
Investigators at Moffitt are certain that their cancer – risk gene signature for NSCLC gene signature tool because it is a proliferative gene signature associated with both cancer risk and progression . Continue reading “Not unique characteristic derived in other gene signatures for different types of tumors seen.”